All companies
Visit website
Neurotez Inc.
OperatingBiotech · Founded 2005
Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.
Post-money valuation ⓘ
$45.3M
As of Jan 2023 · from Neurotez Inc. Common Stock 4 · pre-money + amount raised, not a traded price
Total raised
$399,508
Across 4 rounds since 2018
Latest share price
$4.00
Neurotez Inc. Common Stock 4 offering price
Financials
FY2015–FY2022 · from SEC filings · hover any figure for its source$8K
−$257K
2015
$0
−$24K
2016
$0
2017
$0
2018
$0
−$367K
2019
$9K
$199K
2020
$0
−$225K
2021
$0
−$37K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$8,002
$0
$0
$0
$0
$9,115
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
$0
$0
Gross margin
100%
—
—
—
—
100%
—
—
Net income
-$257,389
-$23,705
$0
$0
-$367,295
$198,521
-$225,409
-$36,688
Taxes paid
$0
$0
$0
$0
$0
$1,250
$0
$0
Balance sheet
Cash
$126
$60
$302
$7,533
$283
$5,882
$109,331
$629
Accounts receivable
$0
$0
$0
$0
$0
$0
$0
$0
Total assets
$126
$60
$221,123
$217,892
$176,536
$164,744
$258,975
$130,371
Short-term debt
$0
$13,135
$0
$0
$396,332
$50,625
$0
$0
Long-term debt
$0
$0
$43,335
$55,960
$26,000
$20,000
$97,218
$121,029
Total liabilities
$0
$13,135
$43,335
$55,960
$422,332
$70,625
$97,218
$121,029
Other
Headcount
—
11
—
8
—
6
6
7
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$44.9M
post-money
$45.3M
post-money
Neurotez Common Stock 3
Neurotez Inc. Common Stock 4
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $16K / $500KPost-money $45.3M
Raised $33.8K / $281.1KInvestors 32Post-money $44.9M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 3 of 9 annual reports (FY2017–FY2025)
32 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 36 filings on EDGARSource: ManualCIK 0001725567Share price $4.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.